NCA
UTHR icon

New Century Advisors’s United Therapeutics UTHR Stock Holding History

New Century Advisors’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$187K Sell
893
-176
-16% -$39.3K 0.23% 49
2022
Q2 		$252K Buy
1,069
+62
+6% +$12.6K 0.29% 41
2022
Q1 		$180K Buy
1,007
+196
+24% +$37.3K 0.15% 68
2021
Q4 		$175K Buy
+811
New +$159K 0.17% 74

Other funds holding UTHR

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

New Century Advisors's UTHR Position: Q3 2022 in Review

New Century Advisors reduced its United Therapeutics (UTHR) stake by 16% in Q3 2022, selling an estimated $39.3K and leaving 893 shares worth $187K. The position accounts for 0.23% of the portfolio, ranked #49.

New Century Advisors first reported a position in UTHR in Q4 2021 and has held it in 4 quarters since. The position peaked at $252K in Q2 2022. 461 funds tracked by Wall St. Rank hold UTHR as of Q3 2022.

  • New Century Advisors held 893 shares of United Therapeutics worth $187K as of Q3 2022.
  • New Century Advisors sold 176 United Therapeutics shares in Q3 2022, an estimated $39.3K.
  • United Therapeutics made up 0.23% of New Century Advisors's portfolio in Q3 2022, its #49 holding.
  • New Century Advisors first reported a position in United Therapeutics in Q4 2021 and has held it in 4 quarters since.
  • New Century Advisors's United Therapeutics position peaked at $252K in Q2 2022.
  • 461 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2022.

Based on New Century Advisors's 13F filing for Q3 2022, filed 13 Oct 2022.